Nucleix Ltd.

📍 Rehovot, Israel🗓 Founded 2008👥 63 employees💰 Last funded May 2020
Biotechnology Research🌐 nucleix.com
Website LinkedIn
Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection at a time when intervention can bring the greatest impact for patients. Leveraging NGS-based and PCR-based technology to identify methylation changes, the Company’s pioneering testing approach uses methylation-based identification for early-stage and recurring cancer detection. The Company’s non-invasive EpiCheck® delivers highly accurate and sensitive results, all while providing a seamless testing option for physicians, patients, and the healthcare system. The Company is building an EpiCheck® franchise, beginning with the Bladder EpiCheck® kit, CE-marked and available in Europe for primary and recurrent bladder cancer and upper tract urinary cancer, and FDA 510(k) cleared for bladder cancer recurrence in the United States. The Company is advancing its Lung EpiCheck® test towards commercialization for high-risk individuals while evaluating additional tests for other high-risk diseases.
3
Total investors
1
Early stage
0
Mid stage
1
Late stage
2008
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Israel
2
United States
1
Investor activity2008–2020 · investors recorded per year
200812016120201
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Nucleix Ltd.?
Nucleix Ltd. has 3 investors on record on gritt.io, including 1 early-stage backers and 1 late-stage investors.
When did Nucleix Ltd. last raise funding?
The most recent investment in Nucleix Ltd. recorded on gritt.io was in May 2020.
When was Nucleix Ltd. founded?
Nucleix Ltd. was founded in 2008.
What industry is Nucleix Ltd. in?
Nucleix Ltd. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Nucleix Ltd. based?
Nucleix Ltd. is headquartered in Rehovot, Israel.